60 Binney St
About bluebird bio
bluebird bio is leading the gene therapy revolution. We have nearly 15 years of scientific and clinical experience at the forefront of gene therapy, with deep expertise in rare diseases and immuno-oncology, a proven scientific and lentiviral-based manufacturing platform, and a complementary set of tools such as gene editing.
We are a patient- and purpose-driven, product-oriented organization. Our diverse flock of bluebirds is united by a singular focus: a passionate commitment to changing the lives of patients and supporting each other on this journey. At bluebird bio, we will work like crazy with a never-give-up, little-but-mighty attitude, as exemplified by our namesake, the Eastern Bluebird.
we are always innovating, never stopping and never giving up.
Stock symbol: BLUE
Stock exchange: NASDAQ
Our birds are constantly reminded of the difference they can make on the lives of patients and in the lives of their fellow birds – no matter what their title may be. Whether it’s running a successful experiment in the lab, developing a new and efficient process for your team, being an inspiring mentor for those around you, or always being a friendly face in the morning, we can all make an impact and we can all make a difference. How will you Make Your Mark?
384 articles with bluebird bio
bluebird bio and National Resilience signed a strategic alliance around cell therapies. As part of the deal, Resilience is buying bluebird’s manufacturing facility in Research Triangle Park, keeping more than 100 staffers.
The designation was awarded for RVx201, a live-attenuated therapeutic vaccine the company is developing for genital herpes resulting from the herpes simplex type 2 (HSV-2) virus.
bluebird bio Receives EC Approval for SKYSONA™ (elivaldogene autotemcel, Lenti-D™) Gene Therapy for Patients Less Than 18 Years of Age With Early Cerebral Adrenoleukodystrophy (CALD) Without Matched Sibling Donor
bluebird bio, Inc. announced that the European Commission has granted marketing authorization of SKYSONA™, a one-time gene therapy for the treatment of early cerebral adrenoleukodystrophy in patients less than 18 years of age with an ABCD1 genetic mutation, and for whom a human leukocyte antigen -matched sibling hematopoietic stem cell donor is not available.
bluebird bio Announces Positive Recommendation by PRAC Regarding Article 20 Safety Referral Review of ZYNTEGLO™ Gene Therapy for Transfusion-Dependent β-thalassemia and Marketing to Resume in EU
bluebird bio, Inc . (Nasdaq: BLUE) today announced that the European Medicines Agency's (EMA) Pharmacovigilance Risk Assessment Committee (PRAC) has concluded based on the review of all available data that the benefit-risk balance of medicinal products containing ZYNTEGLO™ (betibeglogene autotemcel gene therapy) remains favorable.
bluebird bio is hitting back at Spark Therapeutics over the use of the word “spark” involving the company’s “Be the Spark” campaign against sickle cell disease.
betibeglogene autotemcel (beti-cel) One-Time Gene Therapy for β-thalassemia Continues to Demonstrate Durable Efficacy Across Pediatric and Adult Patient Populations and All Genotypes in Data Presented at EHA2021 Virtual
bluebird bio, Inc. presented data from several studies of betibeglogene autotemcel gene therapy in adult, adolescent and pediatric patients with transfusion-dependent β-thalassemia.
The 2021 EHA is in full swing. BioSpace is rounding up several presentations from the past two days. Here are some of them.
bluebird bio Announces the Lifting of FDA Clinical Hold for Sickle Cell Disease and β-Thalassemia Studies
bluebird bio, Inc . (Nasdaq: BLUE) today announced that the U.S. Food and Drug Administration (FDA) has lifted the clinical holds on the Phase 1/2 HGB-206 and Phase 3 HGB-210 studies of LentiGlobin for sickle cell disease (SCD) gene therapy (bb1111) for adult and pediatric patients with SCD, and the Phase 3 Northstar-2 (HGB-207) and Northstar-3 (HGB-212) studies of betibeglogene autotemcel gene therapy
The FDA lifted the clinical holds on bluebird bio’s sickle gene therapy and its betibeglogene autotemcel gene therapy for adults, adolescents and children with TDT.
bluebird bio, Inc. Reports Inducement Grants to CCO Tom Klima Under Nasdaq Listing Rule 5635(c)(4) - June 02, 2021
bluebird bio, Inc. announced that the Compensation Committee of the Company’s Board of Directors approved inducement grants of stock options to purchase a total of 50,000 shares of common stock and 25,000 restricted stock units to its Chief Commercial Officer Tom Klima with a grant date of June 1, 2021.
BioSpace looks at five of the top investor companies that support life sciences companies across the industry.
Gene therapy is still very much cutting-edge with the potential to cure incurable genetic diseases. Here’s some recent news in the space.
bluebird bio Receives Positive CHMP Opinion for SKYSONA™ (elivaldogene autotemcel, Lenti-D™) Gene Therapy for Patients Less Than 18 Years of Age with Early Cerebral Adrenoleukodystrophy (CALD)
SKYSONA is the first and only gene therapy recommended for approval for patients with CALD, a progressive, neurodegenerative disease As of the data cutoff date, 90% of patients (27/30) treated with SKYSONA in the pivotal ALD-102 clinical study met the primary endpoint of major functional disability (MFD)-free survival at two years of follow-up
Long-Term Data from Pivotal KarMMa Study Continue to Demonstrate Deep and Durable Responses and Predictable Safety Profile with Bristol Myers Squibb and bluebird bio’s Abecma (idecabtagene vicleucel) in Relapsed or Refractory Multiple Myeloma
Data from pivotal KarMMa study to be presented at ASCO21 show 24.8-month median overall survival in triple-class exposed multiple myeloma
bluebird bio to Present Data from Its Severe Genetic Disease and Oncology Portfolios During the EHA2021 Virtual Congress
bluebird bio, Inc . (Nasdaq: BLUE) announced today that data from its gene therapy programs for transfusion-dependent β-thalassemia (TDT) and sickle cell disease (SCD) and its cell therapy program for relapsed or refractory multiple myeloma (R/RMM) will be presented during EHA2021 Virtual, the 26 th Annual Congress of the European Hematology Association, taking place June 9-17, 2021.
Bluebird bio reported first-quarter earnings, the approval of Abecma, the first CAR-T therapy for relapsed or refractory multiple myeloma, and its spinout, 2seventy bio, and its leadership.
bluebird bio, Inc. reported financial results and business highlights for the first quarter ended March 31, 2021 and shared recent operational progress.
bluebird bio, Inc. (NASDAQ: BLUE) today announced that members of the management team will participate in the following upcoming investor conferences: BofA Securities 2021 Health Care Conference, Thursday, May 13, at 9:30 am ET 2021 RBC Capital Markets Global Healthcare Conference, Wednesday, May 19, at 1:55 pm ET
PsiOxus and bluebird bio Present Novel Data Combining PsiOxus T-SIGn Platform with CAR-T Therapy to Clear Primary Tumors and Metastases
PsiOxus Therapeutics, Ltd., a clinical stage oncology company re-programming the tumor microenvironment to overcome the central challenge of resistance to therapy, and bluebird bio, Inc. presented preclinical data at the American Association for Cancer Research Annual Meeting 2021.
Davidson is one of three new executives to join Cambridge, Mass.-based Tessera.